The psychedelic-themed event will be hosted by Proactive’s Christine Corrado and kicks off on Tuesday at 1 PM ET.
Toronto-based Aion Therapeutic Inc (CSE:AION) recently filed five patent applications with the US Patent and Trademark Office related to the combination of medical cannabis with edible and psychedelic mushrooms.
The applications include formulations designed to treat a variety of conditions, including cancer, psychiatric disorders, addiction, viral diseases, obesity and inflammatory disorders.
Aion’s combinatorial treatment formulation discovery platform relies on artificial intelligence (AI) techniques. By utilizing AI, the company plans to create a full line of therapeutic products that includes combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals, as well as individualized treatments for personalized medicine using human genome and other data.
Executive chairman Dr Stephen Barnhill will take participants through the firm’s pharmaceutical research and product development. Aion also operations in Jamaica, where psychedelics are more available.
"Jamaica provides Aion Therapeutic an incredibly unique opportunity in that it is one of the very few countries in the world where mushrooms have never been made illegal and are openly sold,” Barnhill said recently.
“It is worth noting that Aion Therapeutic has this incredible research and development opportunity through our partnership with Apollon Formularies Jamaica Ltd, a CLA-licensed medical cannabis company,” Barnhill added. “This partnership allows Aion Therapeutic to legally discover these unique medical cannabis and medical mushroom combinations for therapeutic product formulations. We believe that we can build a large portfolio of blocking patents while most of the rest of the world faces legal hurdles that limit efforts in this type of research and discovery."
Contact Angela at firstname.lastname@example.org
Follow her on Twitter @AHarmantas